Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul-Dec;27(8):665-678.
doi: 10.1080/14728222.2023.2247563. Epub 2023 Aug 22.

Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update

Temugin Berta  1 , Judith A Strong  1 , Jun-Ming Zhang  1 , Ru-Rong Ji  2   3
Affiliations
Review

Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update

Temugin Berta et al. Expert Opin Ther Targets. 2023 Jul-Dec.

Abstract

Introduction: Current treatments for chronic pain are inadequate. Here, we provide an update on the new therapeutic strategies that target dorsal root ganglia (DRGs) in the peripheral nervous system for a better and safer treatment of chronic pain.

Areas covered: Despite the complex nature of chronic pain and its underlying mechanisms, we do know that changes in the plasticity and modality of neurons in DRGs play a pivotal role. DRG neurons are heterogenous and offer potential pain targets for different therapeutic interventions. We discuss the last advancements of these interventions, which include the use of systemic and local administrations, selective nerve drug delivery, and gene therapy. In particular, we provide updates and further details on the molecular characterization of primary sensory neurons, new analgesics entering the market, and future gene therapy approaches.

Expert opinion: DRGs and primary sensory neurons are promising targets for chronic pain treatment due to their key role in pain signaling, unique anatomical location, and the potential for different targeted therapeutic interventions.

Keywords: Chronic pain; dorsal root ganglia; gene therapy; primary sensory neurons; therapeutic interventions.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest:

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1:
Figure 1:. Administration routes to target DRGs and heterogeneity of primary sensory neurons.
(A) In chronic pain conditions, DRG neurons go through significant cellular and molecular changes that can be targeted for therapy. This can be achieved through local drug delivery methods such as peripheral nerve, intraganglionic, or intrathecal injections. Traditionally, primary sensory neurons have characterized by their morphology, electrophysiological properties and expression of unique proteins, such as parvalbumin (PVALB), neurofilament high (NFH), and peripherin (PRPH). (B) Single-cell RNAseq has revealed an additional heterogeneity of primary sensory neurons, which can be further characterized by the expression of transcripts such as parvalbumin (Pvalb), neurotrophin receptor tyrosine kinases (Ntrk2 and Ntrk3), neuropeptide somatostatin (Sst), substance P (Tac1), calcitonin gene-related peptide (Calca), and transient receptor potential cation channel 8 (Trpm8). Expression of these markers across primary sensory neuron subsets were derived from published RNA-seq data [31] (reproduced under CC-BY). (C) UMAP of Seurat-integrated DRG neurons across various species colored by DRG neuronal subtypes [23] (reproduced under CC-BY), and single-cell expression of TRPV1 in mouse and human DRG neuronal subtypes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Collaborators GDaI. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020. Oct 17;396(10258):1204–1222. - PMC - PubMed
    1. Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019. Jan;160(1):19–27. - PubMed
    1. Scholz J, Woolf CJ. Can we conquer pain? Nature Neuroscience. 2002;5(S11):1062–1067. - PubMed
    1. Fitzcharles M-A, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. The Lancet. 2021;397(10289):2098–2110. - PubMed
    1. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. The Lancet. 2021;397(10289):2082–2097. - PubMed

Publication types

LinkOut - more resources